Abstract
DNA has become a major target for clinical laboratory testing over the past 5 yr, and RNA testing is emerging for infectious disease and gene expression (1). To normalize laboratory results across different technology platforms as well as between laboratories, standardized reagents will become increasingly important. Reliable standards promote the speed at which a diagnostic test can be offered, as well as third-party reimbursement. Standardized control reagents ensure the ability of diagnostic laboratories to pass proficiency testing and quality assurance/quality control (QA/QC) measurements (2). Consensus guidelines endorsed by professional societies and governmental agencies provide a framework for determining standardization needs. In its role supporting US science and industry, the National Institute of Standards and Te c hnology (NIST), a nonregulatory agency of the US Department of Commerce, provides physical and chemical standards in support of national commerce, manufacturing, and science (3). These materials are available internationally as Standard Reference Materials (SRMs) for use by industry developing assays and/or technology platforms for diagnostic use, by regulatory agencies ensuring the quality and efficacy of these assays, and by clinical laboratories providing diagnostic tests for patients. Traditionally, NIST responds to standard needs as defined by these communities. Consensus is developed through NIST workshops attended by representatives of these communities as well as direct request by other governmental agencies. Specific examples of ongoing programs within the Biotechnology Division at NIST are described in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barker, P. E., Watson, M. S., Ticehurst, J. R., Colbert, J. C., and O’Connell, C. D. NIST physical standards for DNA-based medical testing. J. Clin. Lab. Anal. 16:5–10, 2002.
American College of Medical Genetics. Standards and Guidelines for Clinical Genetics Laboratories, 2nd ed., American College of Medical Genetics, Bethesda, MD.
Schooley, J. F. Responding to National Needs: The National Bureau of Standards Becomes the National Institute of Standards and Technology. 1969–1993.: US Government Printing Office Washington, DC, 2000.
4. Wells, R. D. and Warren, S. T. (eds.). Genetic Instabilities and Hereditary Neurological Disease. Academic, San Diego, CA, 1998.
Jakupciak, J. P. and Wells, R. D. Genetic instabilities of triplet repeat sequences by recombination. Life 50:355–359, 2000.
Evers-Kiebooms, G., Harper, P., Zoeteweij, M., et al. Predictive DNA-testing for Huntington’s disease and reproductive decision making: a European collaborative study. Eur. J. Hum. Genet. 10: 167–176, 2002.
O’Connell, C. D., Richie, K. L., Jakupciak, J. P., Amos, J., and Atha, D.H. Standardization of PCR amplification for fragile X trinu-cleotide repeat measurements. Clin. Genet. 61:13–20, 2002.
O’Connell, C. D. Standards for Nucleic Acid Diagnostic Applications, NIST, Gaithersburg, MD, 1998.
9. Emery, A. E. (ed.) Principles and Practice of Medical Genetics. Churchill Livingstone, Edinburgh, UK, 1997.
Chastain, P. D., Eichler, E. E., Kang, S., Nelson, D. L., Levene, S. D., and Sinden, R. R. Anomalous rapid electrophoretic mobility of DNA containing triplet repeats associated with human disease genes. Biochemistry. 34:16,125–16,131, 1995.
Eng, C., Brody, L. C., Wagner, T. M. U., et al. Interpreting epidemi-ological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J. Med. Genet. 38:824–833, 2001.
Kristensen, V. N., Kelefiotis, D., Kristensen, T., and Borresen-Dale, A-L. High-throughput methods for detection of genetic variation. Biotechniques 30:318–332, 2001.
Ellis, L. A., Taylor, C. F., and Taylor, G. R. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum. Mutat. 15:556–564, 2000.
Cotton, R. G. H. Mutation detection 2001: novel technologies, developments and applications for analysis of the human genome. Hum. Mutat. 19:313–314, 2002.
Cotton R. G. H. Slowly but surely towards better scanning for mutations. Trends Genet. 13:43–45, 1997.
O’Connell, C. D., Tully, L., Devaney, J. M., Marino, M., Jakupciak, J. P., and Atha, D. H. Renewable standard reference material for the detection of TP53 mutations. Mol. Diagn. 7:85–97, 2003.
O’Connell, C. D., Barker, P. E., Marino, M., et al. Molecular bio-markers used to detect cellular/genetic damage in tissue engineered skin, Schuttle, E. and Picciolo, G. L., eds., Tissue Engineered Medical Products. ASTM, West Conshohocken, PA, 2003.
Sunar-Reeder, B., Aydemir, S., Khan, A. R., et al. Use of TP53 reference materials to validate mutations in clinical tissue specimens by single-strand conformational polymorphism analysis. Mol. Diagn. 8:123–130, 2004.
Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. P53 mutations in human cancer. Science 253:49–53, 1991.
Vogelstein, B. and Kinzer, K. p53 function and dysfunction. Cell 70:523–526, 1992.
Somlo, G., Simpson, J. F., Frankel, P., et al. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br. J. Cancer 87:281–288, 2002.
Liu, M. C. and Gelmann, E. P. p53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 29:246–257, 2002.
Geisler, S., Lonning P. E., Aas, T.,et al. Influence of TP53 gene alterations and c-erb B-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505–2512, 2001.
Atha, D. H, Wenz, H-M., Morehead, H., Tian, J., and O’Connell, C. D. Detection of p53 point mutations by single strand conformation polymorphism: analysis by capillary electrophoresis. Electrophoresis 19:172–179, 1998.
Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA 86:2766–2770, 1989.
Eng, C., Brody L. C., Wagner, T. M. U., et al. Interpreting epidemi-ological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J. Med. Genet. 38:824–833, 2001.
Anderson, T. I. and Borresen, D. A.-L. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn. Mol. Pathol. 4:203–211, 1995.
Keller, G., Hartmann, A., Mueller, J., and Hofler, H. Denaturing high pressure chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab. Invest. 81:1735–1737, 2001.
Ahrendt, S. A., Halachmi, S, Chow, J. T, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. USA 96:7382–7387, 1999.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jakupciak, J.P., O’Connell, C.D. (2006). Standards and Standardization of Molecular Diagnostics. In: Coleman, W.B., Tsongalis, G.J. (eds) Molecular Diagnostics. Humana Press. https://doi.org/10.1385/1-59259-928-1:243
Download citation
DOI: https://doi.org/10.1385/1-59259-928-1:243
Publisher Name: Humana Press
Print ISBN: 978-1-58829-356-5
Online ISBN: 978-1-59259-928-8
eBook Packages: MedicineMedicine (R0)